Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
DOUBLE SALT COMPOUND OF FLAVONE GLYCOSIDE-ORGANIC AMINE ANTI-TUMOR AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/089593
Kind Code:
A1
Abstract:
The present application relates to the technical field of pharmaceutical chemistry, and in particular relates to a double salt compound of a flavone glycoside-organic amine anti-tumor agent, a preparation method therefor and the use thereof. In the double salt compound of the flavone glycoside-organic amine anti-tumor agent prepared by means of the present application, the flavone glycoside has a structural general formula as shown in formula (I), wherein R1-R9 are independently selected from -H, -OH, C1-C6 alkyl, alkoxy or substituted alkyl, and at least one of R1 and R2 is -OH. The present application also relates to a method for preparing the double salt compound. The present application further relates to a pharmaceutical composition containing a therapeutically effective amount of the double salt compound and the use thereof. Furthermore, the present application also relates to a double salt nanoparticle, which is obtained by means of nano-grinding repeatedly the double salt compound, and the use thereof.

Inventors:
WANG HUALU (CN)
WANG LUYING (CN)
Application Number:
PCT/CN2021/127477
Publication Date:
May 05, 2022
Filing Date:
October 29, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HANGZHOU LALIN INTELLIGENCE SCIENCE AND TECH CO LTD (CN)
International Classes:
C07H17/07; A61K31/454; A61K31/506; A61K31/519; A61K31/7048; A61P35/00; A61P35/02; C07D401/04; C07D401/14; C07D417/12; C07D487/04; C07H1/00
Foreign References:
CN101732417A2010-06-16
CN107641140A2018-01-30
CN113801181A2021-12-17
CN112010849A2020-12-01
Other References:
LI WENLIANG, ZENG JIAN-GUO, ZHANG XUE, LIU FA-BAO, DU FANG-LU, XU LI: "The 1H NMR Spectral Analyses of Chelerytrine-baicalin, Sanguinarine-baicalin and Related Ion-pair Compounds", CHEMICAL WORLD, SHANGHAISHI HUAXUE HUAGONG XUEHUI-WUXI INSTITUTE OF LIGHT INDUSTRY, 214086, CN, vol. 53, no. 4, 30 April 2012 (2012-04-30), CN , pages 211 - 213, XP055924776, ISSN: 0367-6358, DOI: 10.19500/j.cnki.0367-6358.2012.04.006
ZHANG JUAN, LI DONG-XIA: "Progress of Studies on Antitumor Effect of Berberine", MEDICAL RECAPITULATE, YIXUE ZONGSHU, CN, vol. 20, no. 4, 28 February 2014 (2014-02-28), CN , pages 634 - 637, XP055924777, ISSN: 1006-2084, DOI: 10.3969/j.issn.1006-2084.2014.04.019
TIAN SHIJIE, LIU ZHAOYING;LIU YISONG;ZENG JIANGUO: "Research progress of pharmacokinetics in sanguinarine and chelerythrine", HEILONGJIANG ANIMAL SCIENCE AND VETERINARY MEDICINE, no. 1, 15 June 2016 (2016-06-15), pages 57 - 60, XP055924779, DOI: 10.13881/j.cnki.hljxmsy.20160615.001
NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA: "Guidelines for Clinical Applications of Novel Anti-Tumor Drugs, 2019 Edition", JOURNAL OF MULTIDISCIPLINARY CANCER MANAGEMENT (ELECTRONIC VERSION), vol. 6, no. 1, 31 January 2020 (2020-01-31), pages 16 - 47, XP009536362, ISSN: 2096-2940, DOI: 10.12151/JMCM.2020.01-04
Attorney, Agent or Firm:
ACIP LAW OFFICES (CN)
Download PDF: